Developer docs
API playgroundTry for free, no card

Search company profiles

Highlight Capital

Full company profile

uuid00002ct

Namestring
Highlight Capital
Legal namestring
弘晖基金
Websiteurl
hlc.com.cn
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Highlight Capital (弘晖基金, HLC) is a Shanghai-headquartered Chinese venture capital and private equity firm founded in 2014, operating dual-currency fund vehicles across the RMB and USD (HLC USD Fund) denominations. The firm focuses on two primary investment verticals: Healthcare & Life Sciences (covering frontier biotechnology, innovative drugs, medical devices, diagnostics, CRO/CDMO services, gene and cell therapies, and precision medicine) and Technology & Manufacturing (semiconductors, advanced manufacturing, new materials, AI, and embodied AI/humanoid robotics). As of late 2025, the firm has invested in 200+ portfolio companies, achieved 30+ IPOs across HKEX, Nasdaq, STAR Market, and BSE, and reports 12 years of equity investment and fund management experience. Headcount is reported at 11-50 employees, with offices in Shanghai (headquarters), Beijing, Shenzhen, Nanjing, and Chongqing.

HLC's business model is that of a traditional PE/VC fund manager: it earns recurring management fees across multiple fund vehicles (RMB growth fund, USD fund, Chongqing biomedical QFLP fund, Chongqing New Quality Productivity Fund, Nanjing Angel Fund) and performance-based carried interest and equity gains from exits. The 2025-2026 exit track record includes the $1.5B acquisition of portfolio company Arthrosi Therapeutics, a $570M Medilink-Roche licensing deal, the $800M+ Avenzo transaction, and multiple FDA approvals and global pharma licensing deals (GSK $500M+, Merck-Lilly up to $910M). Notable investees span Mindray, Tigermed, United Imaging, Pharmaron, Yuwell, Sansure, Smoore International, WuXi AppTec, and Spirit AI (a unicorn in embodied AI). The firm's competitive positioning rests on a research-driven investment framework grounded in chemistry, biology, materials engineering, electronics, and mechanical engineering, combined with a system-level post-investment empowerment model that channels capital, strategic guidance, and ecosystem introductions to portfolio companies.

Distribution and deal flow operate through three reinforcing channels: direct field-based sourcing by investment teams in Shanghai, Beijing, and Shenzhen; event- and community-led ecosystem development via the HLC Family network (200+ portfolio companies), industry conferences, and cross-border activity weeks in Korea, Japan, and Southeast Asia; and government/district partnerships including Chongqing International Bio-city, Wuxi Huishan, Huangpu Central Sci-Innovation Zone, and Seoul Metropolitan Government. Marketing is anchored on WeChat official accounts (HLC Family and HLC Event branded channels) and a corporate news portal, supplemented by analyst recognitions such as Zero2IPO China VC Top 25 and Healthcare Investment Institution Top 30 (2025). Leadership includes Founder & CEO Steven Wang and Founding Partner Zhao Gang, with VP Alvin Yan and Director Pascal-Christian Sarana.

Short descriptiontext

Highlight Capital (弘晖基金/HLC) is a Shanghai-headquartered Chinese venture capital and private equity firm founded in 2014, investing across healthcare/life sciences and technology/manufacturing via RMB and USD fund vehicles. It serves early- and growth-stage Chinese companies with a 200+ portfolio and 30+ IPO track record.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital, private equity, healthcare investment, fund management, growth equity
Industry2 codes
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAGAH
Thematic / Sector-Focused Multi-Manager Platforms
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Other Financial Investment Activities5239
SIC code2 codes
  • Investment Advice6282
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Private Equity and Venture Capital Fund Management
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Fund management fees
TypeSubscription Recurring
Description

Recurring management fees earned across multiple RMB and USD vehicles, including RMB growth funds, USD funds (HLC USD fund), regional thematic funds (e.g., Chongqing New Quality Productivity Fund, Chongqing biomed QFLP fund, Nanjing Angel Fund), and angel-stage funds. These fees form the recurring revenue base of the fund management business.

hlc.com.cn
2Carried interest and investment returns from exits
TypeTransaction Fee
Description

Performance-based carried interest and equity gains from successful portfolio exits. Demonstrated by 30+ IPOs of portfolio companies and major exits such as the $1.5B acquisition of Arthrosi Therapeutics, $950M acquisition of Promis Biologics (普米斯), $800M+ Avenzo deal, multiple FDA approvals, and licensing deals (Roche $570M, GSK $500M+, Merck-Lilly up to $910M). Returns are realized through IPO listings (HKEX, Nasdaq, STAR Market, BSE), M&A, and strategic licensing transactions.

hlc.com.cn
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Highlight Capital (弘晖基金/HLC) is a private venture capital and private equity fund management firm that invests in early- and growth-stage Chinese companies across two flagship verticals: Healthcare & Life Sciences (biotech, innovative drugs, medical devices, diagnostics, CRO/CDMO) and Technology & Manufacturing (semiconductors, advanced manufacturing, new materials, AI, embodied AI/robotics). Capital is deployed through a family of complementary fund vehicles including RMB growth funds, the HLC USD Fund, the Chongqing Biomedical QFLP Fund, the HLC Chongqing New Quality Productivity Fund, and the HLC Nanjing Angel Fund, with system-level post-investment empowerment services to portfolio companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 30+ portfolio company IPOs across HKEX, Nasdaq, STAR Market, and BSE
+6 more records
Product overview1 text field

Highlight Capital (弘晖基金 / HLC) is a single integrated venture capital and private equity firm rather than a platform-plus-modules product architecture. Its core offerings are organized around two flagship investment verticals — Healthcare (医疗健康) and Technology & Manufacturing (科技制造) — executed through a family of complementary fund vehicles including the RMB-denominated primary fund, the 弘晖(HLC)美元基金 (USD Fund), the regional 弘晖新质生产力重庆基金 (Chongqing New Quality Productivity Fund) and 弘晖南京天使基金 (Nanjing Angel Fund), and the specialized Chongqing Biomedical QFLP Fund. Together, the Healthcare and Technology & Manufacturing verticals define the investment thesis, while the named fund vehicles enable execution across geographies (Shanghai HQ with Beijing and Shenzhen offices), stages (early/growth), and currencies (RMB and USD). The firm invests independently based on deep research in chemistry, biology, materials science, electronics, and mechanical engineering, and provides systematic post-investment empowerment services to portfolio companies.

Product and service3 records
1Healthcare Investment Line (医疗健康)
CategoryInvestment Vertical - Healthcare & Life Sciences
2Technology & Manufacturing Investment Line (科技制造)
CategoryInvestment Vertical - Technology & Advanced Manufacturing
3HLC USD Fund (弘晖(HLC)美元基金)
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierModerateTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

HLC signed a cooperation agreement with the Seoul Metropolitan Government in 2025-12 to open a new chapter in China-Korea biomed cooperation. This was reinforced by HLC's invitation to the Korean President's China visit event on 2026-01-07. The partnership enables HLC portfolio companies' access to Korean biomed ecosystem, clinical partnerships, and cross-border deal flow.

2Zhejiang University (浙江大学)
Strategic tierModerateTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

Pharmaron (康龙化成), an HLC portfolio company, signed a comprehensive strategic cooperation agreement with Zhejiang University on 2025-07-11. HLC supports and amplifies portfolio-company partnerships of this kind.

hlc.com.cn
3Chongqing International Bio-city (重庆国际生物城)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

HLC established Chongqing's first biomed QFLP fund (Qualified Foreign Limited Partnership fund) within the Chongqing International Bio-city in 2025-04. This was followed by the establishment of the Highlight New Quality Productivity Chongqing Fund (弘晖新质生产力重庆基金) on 2025-12-18. The partnership anchors HLC's western-China biomed investment strategy and provides access to the regional biomed industrial cluster.

hlc.com.cn
4Wuxi Huishan District Government (无锡惠山)
Strategic tierModerateTypeGTM or Marketing PartnerAnnounced on2025-04-01
Description

HLC co-hosted the "Innovation Sets Sail, Huishan-Shenzhen Connection" Wuxi Huishan (Shenzhen) Tech-Finance Cooperation Salon and HLC Angel Fund project roadshow on 2025-04-02. The partnership supports regional deal sourcing, angel-stage investment promotion, and HLC angel fund deployment in the Yangtze River Delta.

hlc.com.cn
5Huangpu Central Sci-Innovation Zone (黄浦中央科创区)
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-11-01
Description

HLC hosted the Huangpu Central Sci-Innovation Zone Innovation Accelerator Camp on 2024-11-25, supporting early-stage company development and regional deal sourcing in Shanghai's Huangpu District.

hlc.com.cn
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Hillhouse is a mega-scale Chinese investment platform with deep healthcare and technology exposure through public and private strategies. It is a much larger incumbent competing for premium Chinese healthcare/tech deals and LP capital alongside HLC.

TypeRegional player
Description

Vivo Capital is a healthcare-focused PE/VC firm primarily operating in the US with growing Asia-Pacific activity, comparable to HLC in vertical focus (healthcare/biotech) but operating from a different geographic base. Useful cross-border healthcare investor comparable.

TypeEmerging player
Description

OrbiMed is a global healthcare-dedicated investment firm with significant Asia-Pacific activity, comparable to HLC in its healthcare-vertical focus and stage coverage. Both invest across pharma, devices, and diagnostics globally.

4Legend Capital (君联资本)
TypeDirect peer
Description

Legend Capital is a top-tier Chinese VC/PE firm with deep healthcare and technology coverage and RMB+USD funds, directly comparable to HLC's healthcare/tech dual-vertical model. Both target growth-stage Chinese companies and have produced multiple listed healthcare and tech names.

TypeDirect peer
Description

CBC Group is a China-focused healthcare investment platform with cross-border capabilities, directly comparable to HLC's healthcare-vertical strategy and RMB+USD fund structure. Both are dedicated healthcare specialists active in Chinese biotech and medtech.

TypeDirect peer
Description

Loyal Valley Capital is a Chinese PE/VC firm with healthcare, technology, and consumer coverage across RMB and USD vehicles, with comparable focus on healthcare innovation and growth-stage Chinese companies to HLC.

TypeDirect peer
Description

FountainVest is a leading Chinese growth-equity and PE investor with significant healthcare and technology exposure, comparable to HLC in stage focus and sector mix. Both deploy RMB and USD capital into Chinese growth-stage companies.

TypeBroad incumbent
Description

HongShan is one of China's largest VC platforms, with broad healthcare and technology exposure across stages and currencies. It is a broader incumbent that competes with HLC on premium Chinese healthcare/tech deals and co-investor allocations.

TypeDirect peer
Description

Qiming is a leading Chinese venture firm with a healthcare and technology focus that closely mirrors HLC's vertical strategy. Both lead multi-stage Chinese investments, participate in global biotech licensing, and maintain RMB+USD fund vehicles; HLC even co-invested in Vivatides Therapeutics' Series A led by Qiming.

TypeDirect peer
Description

IDG Capital is a long-tenured Chinese VC with healthcare and technology coverage across RMB and USD vehicles, comparable in stage, vertical mix, and exit profile to HLC. Both have produced multiple Chinese healthcare IPOs and pursue cross-border investment activity.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers20 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment190 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Highlight Capital

Private Equity and Venture Capital Fund Managementhlc.com.cn

Highlight Capital (弘晖基金/HLC) is a Shanghai-headquartered Chinese venture capital and private equity firm founded in 2014, investing across healthcare/life sciences and technology/manufacturing via RMB and USD fund vehicles. It serves early- and growth-stage Chinese companies with a 200+ portfolio and 30+ IPO track record.

What Highlight Capital does

Highlight Capital (弘晖基金, HLC) is a Shanghai-headquartered Chinese venture capital and private equity firm founded in 2014, operating dual-currency fund vehicles across the RMB and USD (HLC USD Fund) denominations. The firm focuses on two primary investment verticals: Healthcare & Life Sciences (covering frontier biotechnology, innovative drugs, medical devices, diagnostics, CRO/CDMO services, gene and cell therapies, and precision medicine) and Technology & Manufacturing (semiconductors, advanced manufacturing, new materials, AI, and embodied AI/humanoid robotics). As of late 2025, the firm has invested in 200+ portfolio companies, achieved 30+ IPOs across HKEX, Nasdaq, STAR Market, and BSE, and reports 12 years of equity investment and fund management experience. Headcount is reported at 11-50 employees, with offices in Shanghai (headquarters), Beijing, Shenzhen, Nanjing, and Chongqing.

HLC's business model is that of a traditional PE/VC fund manager: it earns recurring management fees across multiple fund vehicles (RMB growth fund, USD fund, Chongqing biomedical QFLP fund, Chongqing New Quality Productivity Fund, Nanjing Angel Fund) and performance-based carried interest and equity gains from exits. The 2025-2026 exit track record includes the $1.5B acquisition of portfolio company Arthrosi Therapeutics, a $570M Medilink-Roche licensing deal, the $800M+ Avenzo transaction, and multiple FDA approvals and global pharma licensing deals (GSK $500M+, Merck-Lilly up to $910M). Notable investees span Mindray, Tigermed, United Imaging, Pharmaron, Yuwell, Sansure, Smoore International, WuXi AppTec, and Spirit AI (a unicorn in embodied AI). The firm's competitive positioning rests on a research-driven investment framework grounded in chemistry, biology, materials engineering, electronics, and mechanical engineering, combined with a system-level post-investment empowerment model that channels capital, strategic guidance, and ecosystem introductions to portfolio companies.

Distribution and deal flow operate through three reinforcing channels: direct field-based sourcing by investment teams in Shanghai, Beijing, and Shenzhen; event- and community-led ecosystem development via the HLC Family network (200+ portfolio companies), industry conferences, and cross-border activity weeks in Korea, Japan, and Southeast Asia; and government/district partnerships including Chongqing International Bio-city, Wuxi Huishan, Huangpu Central Sci-Innovation Zone, and Seoul Metropolitan Government. Marketing is anchored on WeChat official accounts (HLC Family and HLC Event branded channels) and a corporate news portal, supplemented by analyst recognitions such as Zero2IPO China VC Top 25 and Healthcare Investment Institution Top 30 (2025). Leadership includes Founder & CEO Steven Wang and Founding Partner Zhao Gang, with VP Alvin Yan and Director Pascal-Christian Sarana.

Highlight Capital firmographics

Firmographics
Name
Highlight Capital
Legal name
弘晖基金
Website
https://hlc.com.cn
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Highlight Capital (弘晖基金/HLC) is a Shanghai-headquartered Chinese venture capital and private equity firm founded in 2014, investing across healthcare/life sciences and technology/manufacturing via RMB and USD fund vehicles. It serves early- and growth-stage Chinese companies with a 200+ portfolio and 30+ IPO track record.
Ownership category
akta.pro rank

Highlight Capital industry classification

Industry
Product category
Private Equity and Venture Capital Fund Management
NAICS
Portfolio Management and Investment Advice (52394), Other Financial Investment Activities (5239)
SIC
Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAGAH
Thematic / Sector-Focused Multi-Manager Platforms
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms

Keywords

  • Venture capital
  • Private equity
  • Healthcare investment
  • Fund management
  • Growth equity

Where Highlight Capital is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices5 records

Markets served

Highlight Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Fund management fees: Recurring management fees earned across multiple RMB and USD vehicles, including RMB growth funds, USD funds (HLC USD fund), regional thematic funds (e.g., Chongqing New Quality Productivity Fund, Chongqing biomed QFLP fund, Nanjing Angel Fund), and angel-stage funds. These fees form the recurring revenue base of the fund management business.
  2. Carried interest and investment returns from exits: Performance-based carried interest and equity gains from successful portfolio exits. Demonstrated by 30+ IPOs of portfolio companies and major exits such as the $1.5B acquisition of Arthrosi Therapeutics, $950M acquisition of Promis Biologics (普米斯), $800M+ Avenzo deal, multiple FDA approvals, and licensing deals (Roche $570M, GSK $500M+, Merck-Lilly up to $910M). Returns are realized through IPO listings (HKEX, Nasdaq, STAR Market, BSE), M&A, and strategic licensing transactions.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Highlight Capital product offering

Product offering

Core offering

Highlight Capital (弘晖基金/HLC) is a private venture capital and private equity fund management firm that invests in early- and growth-stage Chinese companies across two flagship verticals: Healthcare & Life Sciences (biotech, innovative drugs, medical devices, diagnostics, CRO/CDMO) and Technology & Manufacturing (semiconductors, advanced manufacturing, new materials, AI, embodied AI/robotics). Capital is deployed through a family of complementary fund vehicles including RMB growth funds, the HLC USD Fund, the Chongqing Biomedical QFLP Fund, the HLC Chongqing New Quality Productivity Fund, and the HLC Nanjing Angel Fund, with system-level post-investment empowerment services to portfolio companies.

Product overview

Highlight Capital (弘晖基金 / HLC) is a single integrated venture capital and private equity firm rather than a platform-plus-modules product architecture. Its core offerings are organized around two flagship investment verticals — Healthcare (医疗健康) and Technology & Manufacturing (科技制造) — executed through a family of complementary fund vehicles including the RMB-denominated primary fund, the 弘晖(HLC)美元基金 (USD Fund), the regional 弘晖新质生产力重庆基金 (Chongqing New Quality Productivity Fund) and 弘晖南京天使基金 (Nanjing Angel Fund), and the specialized Chongqing Biomedical QFLP Fund. Together, the Healthcare and Technology & Manufacturing verticals define the investment thesis, while the named fund vehicles enable execution across geographies (Shanghai HQ with Beijing and Shenzhen offices), stages (early/growth), and currencies (RMB and USD). The firm invests independently based on deep research in chemistry, biology, materials science, electronics, and mechanical engineering, and provides systematic post-investment empowerment services to portfolio companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Healthcare Investment Line (医疗健康)
  • Technology & Manufacturing Investment Line (科技制造)
  • HLC USD Fund (弘晖(HLC)美元基金)

Quantifiable outcome

  • 30+ portfolio company IPOs across HKEX, Nasdaq, STAR Market, and BSE
  • +6 more outcomes

Companies that use Highlight Capital

Customer profile

Named customers20 records

Segments4 records

Ideal customer profiles2 records

Highlight Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Highlight Capital partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered moderate, flagship and minor.

  • Seoul Metropolitan Government (首尔市)moderateStrategic or Co-development Partner · 1 December 2025HLC signed a cooperation agreement with the Seoul Metropolitan Government in 2025-12 to open a new chapter in China-Korea biomed cooperation. This was reinforced by HLC's invitation to the Korean President's China visit event on 2026-01-07. The partnership enables HLC portfolio companies' access to Korean biomed ecosystem, clinical partnerships, and cross-border deal flow.
  • Zhejiang University (浙江大学)moderateStrategic or Co-development Partner · 1 July 2025Pharmaron (康龙化成), an HLC portfolio company, signed a comprehensive strategic cooperation agreement with Zhejiang University on 2025-07-11. HLC supports and amplifies portfolio-company partnerships of this kind.
  • Chongqing International Bio-city (重庆国际生物城)flagshipStrategic or Co-development Partner · 1 April 2025HLC established Chongqing's first biomed QFLP fund (Qualified Foreign Limited Partnership fund) within the Chongqing International Bio-city in 2025-04. This was followed by the establishment of the Highlight New Quality Productivity Chongqing Fund (弘晖新质生产力重庆基金) on 2025-12-18. The partnership anchors HLC's western-China biomed investment strategy and provides access to the regional biomed industrial cluster.
  • Wuxi Huishan District Government (无锡惠山)moderateGTM or Marketing Partner · 1 April 2025HLC co-hosted the "Innovation Sets Sail, Huishan-Shenzhen Connection" Wuxi Huishan (Shenzhen) Tech-Finance Cooperation Salon and HLC Angel Fund project roadshow on 2025-04-02. The partnership supports regional deal sourcing, angel-stage investment promotion, and HLC angel fund deployment in the Yangtze River Delta.
  • Huangpu Central Sci-Innovation Zone (黄浦中央科创区)minorGTM or Marketing Partner · 1 November 2024HLC hosted the Huangpu Central Sci-Innovation Zone Innovation Accelerator Camp on 2024-11-25, supporting early-stage company development and regional deal sourcing in Shanghai's Huangpu District.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Highlight Capital competitors and assessment

Company assessment

Broad incumbents

  • Hillhouse Capital: Hillhouse is a mega-scale Chinese investment platform with deep healthcare and technology exposure through public and private strategies. It is a much larger incumbent competing for premium Chinese healthcare/tech deals and LP capital alongside HLC.
  • HongShan (Sequoia China): HongShan is one of China's largest VC platforms, with broad healthcare and technology exposure across stages and currencies. It is a broader incumbent that competes with HLC on premium Chinese healthcare/tech deals and co-investor allocations.

Regional players

  • Vivo Capital: Vivo Capital is a healthcare-focused PE/VC firm primarily operating in the US with growing Asia-Pacific activity, comparable to HLC in vertical focus (healthcare/biotech) but operating from a different geographic base. Useful cross-border healthcare investor comparable.

Emerging players

  • OrbiMed: OrbiMed is a global healthcare-dedicated investment firm with significant Asia-Pacific activity, comparable to HLC in its healthcare-vertical focus and stage coverage. Both invest across pharma, devices, and diagnostics globally.

Direct peers

  • Legend Capital (君联资本): Legend Capital is a top-tier Chinese VC/PE firm with deep healthcare and technology coverage and RMB+USD funds, directly comparable to HLC's healthcare/tech dual-vertical model. Both target growth-stage Chinese companies and have produced multiple listed healthcare and tech names.
  • CBC Group (C-Bridge Capital): CBC Group is a China-focused healthcare investment platform with cross-border capabilities, directly comparable to HLC's healthcare-vertical strategy and RMB+USD fund structure. Both are dedicated healthcare specialists active in Chinese biotech and medtech.
  • Loyal Valley Capital: Loyal Valley Capital is a Chinese PE/VC firm with healthcare, technology, and consumer coverage across RMB and USD vehicles, with comparable focus on healthcare innovation and growth-stage Chinese companies to HLC.
  • FountainVest Partners: FountainVest is a leading Chinese growth-equity and PE investor with significant healthcare and technology exposure, comparable to HLC in stage focus and sector mix. Both deploy RMB and USD capital into Chinese growth-stage companies.
  • Qiming Venture Partners: Qiming is a leading Chinese venture firm with a healthcare and technology focus that closely mirrors HLC's vertical strategy. Both lead multi-stage Chinese investments, participate in global biotech licensing, and maintain RMB+USD fund vehicles; HLC even co-invested in Vivatides Therapeutics' Series A led by Qiming.
  • IDG Capital: IDG Capital is a long-tenured Chinese VC with healthcare and technology coverage across RMB and USD vehicles, comparable in stage, vertical mix, and exit profile to HLC. Both have produced multiple Chinese healthcare IPOs and pursue cross-border investment activity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Highlight Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Highlight Capital leadership team

Management profile

Number of profiles

Profiles4 records

Highlight Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Highlight Capital M&A and investment

M&A and investment

M&A

Investments190 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Highlight Capital

What does Highlight Capital do?

Highlight Capital (弘晖基金/HLC) is a private venture capital and private equity fund management firm that invests in early- and growth-stage Chinese companies across two flagship verticals: Healthcare & Life Sciences (biotech, innovative drugs, medical devices, diagnostics, CRO/CDMO) and Technology & Manufacturing (semiconductors, advanced manufacturing, new materials, AI, embodied AI/robotics). Capital is deployed through a family of complementary fund vehicles including RMB growth funds, the HLC USD Fund, the Chongqing Biomedical QFLP Fund, the HLC Chongqing New Quality Productivity Fund, and the HLC Nanjing Angel Fund, with system-level post-investment empowerment services to portfolio companies.

Is Highlight Capital a public or private company?

Highlight Capital is a private company. It is classified as unknown and is currently operating.

When was Highlight Capital founded?

Highlight Capital was founded in 2014. It employs 51 to 100 people.

Where is Highlight Capital based?

Highlight Capital is headquartered in Shanghai, China, in the Asia region.

How does Highlight Capital make money?

Two revenue lines are on record. Fund management fees are the primary driver. The others are carried interest and investment returns from exits.

Who are Highlight Capital's main competitors?

Broad incumbents on record are Hillhouse Capital and HongShan (Sequoia China). Vivo Capital is listed as a regional player. OrbiMed is listed as an emerging player. Direct peers are Legend Capital (君联资本), CBC Group (C-Bridge Capital), Loyal Valley Capital, FountainVest Partners, Qiming Venture Partners and IDG Capital.

Does Highlight Capital have an API?

No public API is recorded for Highlight Capital.

What industry is Highlight Capital in?

Highlight Capital's product category is Private Equity and Venture Capital Fund Management. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAGAH, Thematic / Sector-Focused Multi-Manager Platforms. Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dealroom.coPhrontline raises $40M Series A for bispecific ADC cancer drugs | Dealroom NewsPhrontline Biopharma raised $40 million in a Series A round led by Yuanhe Origin and co-led by Highlight Capital. The funding advances its bispecific ADC programs, with lead program TJ101 (EGFR/B7-H3) beginning clinical enrolment in China and the US. The round supports research on dual-payload ADCs to overcome tumour resistance.Jixin"Purple Micro Technology" completes a new round of financing worth hundreds of millions, with further capital injection into the commercial spacecraft sector.Ziwei Technology completed a new financing round worth hundreds of millions of RMB, with support from new and old shareholders. The funds will support spacecraft development, capacity expansion, and commercial operations. The company's Di'er No. 6 and 11 spacecraft, exceeding 600 kg payload, are scheduled for launch in the second half of this year.PedailyThe commercial spacecraft company Ziwei Technology has completed a new round of financing worth hundreds of millions, with Qiancheng Capital, a subsidiary of Qiancheng Holdings (01945.HK), serving as the financial advisor for this round.Ziwei Technology completed a new financing round worth hundreds of millions, with Qiancheng Capital advising. The company's Di'er No. 5 spacecraft completed commercial operations last year, and its Di'er No. 6 and No. 11 are being produced. The company aims to expand into space manufacturing and commercial applications.Jixin王云鹤创业估值数亿美元,押注多模型 Harness和 Agent-Native ModelTokenRhythm, an AI infrastructure company, completed a new financing round led by Honghui Capital, with participation from other institutions. The company bets on a multi-model routing harness and agent-native models, and its CEO Wang Yunhe previously led Huawei's Pangu large model. Stripe acquired OpenRouter for $7.5 billion in August 2026, highlighting the sector's attention.ChinaventureThe fundamental rhythm has raised tens of millions of dollars in financing.TokenRhythm, an AI infrastructure company, completed a new financing round raising tens of millions of dollars, led by Honghui Fund with participation from Aggregation Capital, Shangshi Capital, and others. The company had previously completed a seed round led by Granite Asia.Fastdata极数“基元律动”累计融资数千万美元 – Fastdata极数Token Rhythm, an AI infrastructure company, announced a new financing round led by Honghui Capital, with participation from Aggregation Capital, Shangshi Capital, and others. The company previously completed a seed round led by Granite Asia. It also launched the TokenRhythm API platform, a one-stop multi-model API service for the Chinese market.36krXunming Biotech has secured an additional Series B financing round totaling 100 million US dollars.-36氪Xunming Biotech raised $100 million in a Series B round, with the first tranche from Granite Asia and subsequent tranches led by industrial investors including Honghui Fund. Existing shareholders Qiming Venture Partners, Matrix Partners China, and New Alliance Capital also participated. The round came just over three months after a $35 million Series A+.36kr"Xunlu Innovation" completed a new round of financing exceeding 100 million yuan at the beginning of this year.-36氪Xunlu Innovation closed a new financing round exceeding 100 million RMB earlier this year, led by Brizan Ventures and Honghui Fund. Proceeds will fund product mass production, new product R&D, and talent pipeline development.36krPoke Robotics has completed a Pre-Series A round of financing valued at hundreds of millions of US dollars.-36氪Poke Robotics completed a Pre-Series A financing round valued at hundreds of millions of US dollars. The round was co-led by Shunwei Capital and Matrix Partners China, with participation from multiple investors, and existing shareholders increased their stakes.JixinThe 'Hatching Robot' has completed a Pre-A round financing of over 100 million dollars.Hatching Robot completed a Pre-A round financing of over 100 million dollars on August 3, 2026, led by Shunwei and Jingwei. Existing shareholders including Xiaomi's investment arm and Honghui Fund increased their stakes. The round also included participation from Jiukun Venture Capital, Junshan Capital, and others.